Navigation Links
China Cord Blood Corporation Files Its Annual Report on Form 20-F/A
Date:10/20/2010

atements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact: China Cord Blood Corporation Ms. Joeling Law Tel: +852-3605-8180 Email: ir@chinacordbloodcorp.com ICR, LLC In New York: Ashley M. Ammon or Christine Duan Tel: +1-646-277-1227 In Beijing: Wen Lei Zheng Tel: +86-10-6599-7968
'/>"/>

SOURCE China Cord Blood Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Reportlinker Adds Industrial Biotechnology China News 1009
2. According to Opurity, Feds Put U.S. Consumers at Risk: PTO Bureaucrats Refuse to Approve Vitamin Companys China-Free Trademark
3. Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco
4. China Cord Blood Corporation Updates Status Regarding Share Repurchase Program
5. China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic
6. China-Biotics Hosted its First Investor Day Event
7. Cord Blood America CEO Matthew Schissler Discusses Projects in China, South America, Afford-A-Cord, and Profitability
8. China Cord Blood Corporation to Launch Warrant Exchange Offer
9. China Cord Blood Corporation Reports First Quarter Fiscal 2011 Financial Results
10. China-Biotics Ranked Number 62 on FORTUNES 100 Fastest-Growing Companies List
11. Reportlinker Adds Advances in Biopharmaceutical Technology in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , Alemania, April 27, 2015 ... nuevo receptor utilizando tecnología de descubrimiento de biomarcador computacional  ... el tratamiento de millones de pacientes con cáncer   ... ha recibido una patente en Europa titulada "Tissue Protective ... Molecular Health de que EPHB4 es un nuevo receptor ...
(Date:4/27/2015)... 2015 Deadly viruses such as Ebola ... of the University City Science Center's Port ... , With a $4.5 million Phase 2 SBIR grant ... Phelix Therapeutics is focused on therapies for unmet ... company is developing first-in-class protease inhibitors based on a ...
(Date:4/27/2015)... , April 27, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today provided commentary on clinical study data ... a poster session at the American Association for ... ADXS31-164 is a novel Lm -LLO immunotherapy ...
(Date:4/27/2015)... HEIDELBERG , Germany , April ... need in treatment of millions of cancer patients   ... a patent in Europe entitled ... Health,s discovery that EPHB4 is a novel receptor for Erythropoietin ... stimulates the production of red blood cells and is ...
Breaking Biology Technology:Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015 2Molecular Health Gains Patent for Novel Receptor Utilizing Computational Biomarker Discovery Technology 2
... Symbol: MSEDMONTON, April 14 /PRNewswire-FirstCall/ - BioMS Medical Corp. ... multiple sclerosis (MS), today announced that the independent Data ... phase III MAESTRO-03 trial of dirucotide in patients with ... recommended that the trial continue as per the protocol. ...
... Therapeutics, Inc., the leader in fragment-based lead discovery ... successful completion of the first phase of its ... of Biogen Idec (Nasdaq: BIIB ). ... to Zenobia,s technology and expertise in structural biology, ...
... Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) ... fiscal 2009 third quarter and nine-month period ended February ... its fiscal year 2009 now ending on February, 28. ... ended February 28, 2009 in the range of $3,400,000 ...
Cached Biology Technology:BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals 2Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 2Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 3Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 4Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 5
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... from layers 3.46 billion years old suggests that not only ... atmosphere was as oxygen rich as it is today, according ... ways similar to the way this rock forms around hydrothermal ... have assumed that the hematite in ancient rocks formed by ...
... scientists from the National Institute of Oceanography and the ... research vessel Polarstern. The cooperative project Lohafex has yielded ... has dampened hopes on the potential of the Southern ... 2 ) and thus mitigate global warming. On 17 ...
... a common ingredient in over-the-counter skin creams. Recent results ... it is associated with major environmental risks. , "The ... in the ocean that has a direct impact on ... Porsbring. When Euorpean authorities assess environmental risks, they ...
Cached Biology News:Deep-sea rocks point to early oxygen on Earth 2Lohafex provides new insights on plankton ecology 2Lohafex provides new insights on plankton ecology 3Lohafex provides new insights on plankton ecology 4Drug used to treat skin conditions is a marine pollutant 2
... Special optically clear polystyrene formulation , High ... applications , Plates are certified for ... variation , Eight-well strips fit snugly ... while in use even if turned upside ...
12 breakable polypropylene strips of 8 wells each held in a rigid frame. Ideal for antibody assays....
...
... Pierce scientists developed the Easy-Titer Human IgM ... a simple, sensitive, and easy-to-perform assay for ... an ELISA. This kit incorporates a simple ... of IgM concentration from 15-500 ng/ml in ...
Biology Products: